Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare · Biotech & pharma
Barcelona, Spain, September 8, 2026 – Orikine Bio (“Orikine”), a biotechnology company pioneering bi-specific cytokines to reprogram the immune system and treat autoimmune and chronic inflammatory disease, today announced changes to its leadership team to support the next stage of corporate development. Sabrina Kuttruff-Coqui, Ph.D., has been appointed Chief Executive Officer, and Joachim Koch, Ph.D., has been appointed Chief Scientific Officer and Chief Development Officer. Both bring decades of biotechnology industry experience to accelerate Orikine's growth strategy and advance Orikine's pipeline. Andreas Muehler, MD, MBA, joins as part-time Chief Medical Officer, bringing a strong medical track record for the transition of lead candidate ORK1 toward an IND submission and first-in-human studies. Pilar Casado García will continue to serve as Chief Financial Officer, ensuring financial and institutional continuity. The Orikine team is expanding at a critical inflection point, as ORK1 advances from preclinical research to IND-enabling studies in inflammatory bowel disease.
Sep 8 · 09:00·GlobeNewswire
Healthcare · Biotech & pharma
GOTHENBURG, Sweden, Sept. 8, 2026 -- Epicyt Pharma AB, a Gothenburg-based clinical-stage biopharmaceutical company developing therapies for impaired intestinal calcium uptake, today announced positive topline results from its Phase 1/2a first-in-human study of BAFA in...
Sep 8 · 08:17·PR Newswire
Biotech & pharma
Montreal, Quebec--(September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward. Dear...
Sep 8 · 07:15·Newsfile
Finance · Biotech & pharma
LOS ANGELES, Sept. 8, 2026 -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)...
Sep 8 · 06:12·PR Newswire
Finance · Biotech & pharma
LOS ANGELES, Sept. 8, 2026 -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
Sep 8 · 06:08·PR Newswire
Finance · Biotech & pharma
New York, New York--(September 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Sep 8 · 02:22·Newsfile
Finance · Biotech & pharma
NEW YORK, Sept. 07, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
Sep 7 · 23:59·GlobeNewswire
Finance · Biotech & pharma
San Diego, California--(September 7, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"), have until September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the Regeneron class action...
Sep 7 · 22:05·Newsfile
Finance · Biotech & pharma
LOS ANGELES, Sept. 07, 2026 -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026 inclusive (the “Class Period”).
Sep 7 · 19:40·GlobeNewswire
Finance · Biotech & pharma
SAN FRANCISCO, Sept. 7, 2026 -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Sep 7 · 17:46·PR Newswire
Finance · Biotech & pharma
LOS ANGELES, Sept. 07, 2026 -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”).
Sep 7 · 17:25·GlobeNewswire
Finance · Healthcare
SAN FRANCISCO, Sept. 7, 2026 -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the...
Sep 7 · 17:22·PR Newswire